The request-for-proposal processes that large health plans run for analytics vendors share a recurring structural problem: they ask MedPricer and Turquoise Health to compete against each other in the same evaluation rubric, then award the contract to whichever platform scores highest on a composite scorecard that measures capabilities the platforms were never designed to share. This is not a procurement failure — it is a conceptual failure, a symptom of the broader confusion in the payer community about what categories of intelligence drive contracting outcomes and in what sequence.\
The Contracting Process as Intelligence Demand
Hospital contract negotiations are not homogeneous events. They unfold in phases — market assessment, benchmark analysis, proposal development, modeling and sensitivity analysis, negotiation, and post-signature performance monitoring — and each phase demands a different kind of intelligence. The phase that Turquoise Health’s rate benchmarking most directly supports is market assessment: understanding, before entering negotiation, what the ambient rate environment looks like and how one’s current rates compare. MedPricer’s contract modeling is most valuable in the proposal development and sensitivity analysis phase: once a target rate range is established, understanding the actuarial implications of getting from A to B.
Payers that have internalized this sequencing tend to use the platforms accordingly — Turquoise Health to set the strategic frame, MedPricer to build the operational case. Payers that treat them as alternatives typically end up choosing based on vendor relationships, prior investment, or platform familiarity rather than on a clear view of which intelligence gap is actually constraining their contracting effectiveness. The analytics investment is then suboptimal not because the tools are deficient but because they are applied to the wrong problem.
Market Structure and Tool Relevance
The relative utility of the two platforms also shifts with market structure in ways that purchasing decisions rarely account for. In concentrated hospital markets — where one or two systems command dominant share and the payer has limited ability to steer patients to alternatives — the actionable intelligence is primarily about contract structure rather than rate comparison. A payer cannot credibly threaten to exclude a system that controls seventy percent of inpatient capacity in a metropolitan area; its leverage lies in negotiating the methodology of payment, the risk distribution, and the performance incentives rather than in citing benchmark rates that the system can simply refuse to honor. MedPricer’s engineering orientation is better suited to this environment. The RAND hospital pricing research has consistently shown that the markets with the highest commercial-to-Medicare rate ratios are exactly those where provider concentration is most extreme — which is also where rate benchmarking is least likely to produce rate reductions, because the benchmark cannot be operationalized into a credible alternative.
In competitive markets — where multiple health systems compete for network inclusion and payers have genuine steering capacity — Turquoise Health’s benchmarking data is more directly actionable. A payer that can credibly threaten to route volume away from a high-priced system, and that can document with precision the size of the rate gap relative to competitors, has leverage that rate benchmarking directly amplifies. The geographic segmentation of the American hospital market means that the optimal analytics strategy for a national insurer varies substantially by region — which creates a portfolio management challenge that most procurement processes are not designed to handle.
The Missing Synthesis
The sophistication gap between how the most analytically capable payers use these tools and how the median health plan approaches hospital contracting remains substantial. Regional Blues plans and mid-sized commercial insurers often lack the internal actuarial and data infrastructure to implement the outputs of either platform effectively — they can generate the benchmark or the contract model but struggle to translate either into negotiating strategy without specialized advisory support. This creates demand for the benefits consultants and actuarial advisors who sit between the platforms and the decisions, translating analytical outputs into contractual positions. That intermediary layer adds friction and cost that a more integrated intelligence offering could potentially reduce. Whether either platform moves in that direction — from analytics tool to full contracting support — will be one of the more interesting strategic questions to watch in the next few years.
